Earnings ·
Amphastar Pharmaceuticals reported second quarter 2026 financial results with net revenues of $183.9 million, a 5%…
AMPHAmphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals reported second quarter 2026 financial results with net revenues of $183.9 million, a 5% increase from the prior year period. GAAP net income was $30.3 million, or $0.67 per diluted share, while adjusted non-GAAP net income reached $40.8 million, or $0.91 per diluted share. The company achieved its first annual net sales milestone for BAQSIMI under an agreement with Eli Lilly, triggering a $100 million payment due in the third quarter of 2026. Amphastar is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products.